Cuili Ma1, Weigang Wang2, Ping Li3. 1. Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, No.126, Xiantai Street, Changchun City, 130033, Jilin Province, People's Republic of China. 2. Department of Urology, The First Hospital of Jilin University, Changchun City, 130021, Jilin Province, People's Republic of China. 3. Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, No.126, Xiantai Street, Changchun City, 130033, Jilin Province, People's Republic of China. pingli303@yeah.net.
Abstract
BACKGROUND: Long non-coding RNA (lncRNA) growth arrest specific transcript 5 (GAS5) negatively regulates interleukin-18 (IL-18) in ovarian cancer, while IL-18 contributes to the development of rheumatoid arthritis (RA). Therefore, GAS5 may also participate in RA. METHODS: GAS5 and IL-18 in plasma of RA patients (n = 60) and healthy controls (n = 60) were measured by RT-qPCR and ELISA, respectively. Linear regression was performed to analyze the correlations between plasma levels of IL-18 and GAS5 in both RA patients and healthy controls. RESULTS: In the present study, we found that plasma GAS5 was downregulated, while IL-18 was upregulated in RA patients than in healthy controls. A significant and inverse correlation between GAS5 and IL-18 was found in RA patients but not in healthy controls. IL-18 treatment did not significantly alter the expression of GAS5 in fibroblast-like synoviocytes, while GAS5 overexpression led to the inhibited expression of IL-18. GAS5 overexpression also resulted in the promoted apoptosis of fibroblast-like synoviocytes. CONCLUSIONS: Therefore, GAS5 overexpression may improve RA by downregulating IL-18 and inducing the apoptosis of fibroblast-like synoviocytes. Key points • The present study mainly showed that overexpression of GAS5 may assist the treatment of RA. • The mechanism of GAS5 for the treatment of RA involves the downregulating inflammatory IL-18 and mediating the apoptosis of fibroblast-like synoviocytes. • GAS5 and IL-8 were correlated in RA patients but not in healthy controls.
BACKGROUND: Long non-coding RNA (lncRNA) growth arrest specific transcript 5 (GAS5) negatively regulates interleukin-18 (IL-18) in ovarian cancer, while IL-18 contributes to the development of rheumatoid arthritis (RA). Therefore, GAS5 may also participate in RA. METHODS:GAS5 and IL-18 in plasma of RApatients (n = 60) and healthy controls (n = 60) were measured by RT-qPCR and ELISA, respectively. Linear regression was performed to analyze the correlations between plasma levels of IL-18 and GAS5 in both RApatients and healthy controls. RESULTS: In the present study, we found that plasma GAS5 was downregulated, while IL-18 was upregulated in RApatients than in healthy controls. A significant and inverse correlation between GAS5 and IL-18 was found in RApatients but not in healthy controls. IL-18 treatment did not significantly alter the expression of GAS5 in fibroblast-like synoviocytes, while GAS5 overexpression led to the inhibited expression of IL-18. GAS5 overexpression also resulted in the promoted apoptosis of fibroblast-like synoviocytes. CONCLUSIONS: Therefore, GAS5 overexpression may improve RA by downregulating IL-18 and inducing the apoptosis of fibroblast-like synoviocytes. Key points • The present study mainly showed that overexpression of GAS5 may assist the treatment of RA. • The mechanism of GAS5 for the treatment of RA involves the downregulating inflammatory IL-18 and mediating the apoptosis of fibroblast-like synoviocytes. • GAS5 and IL-8 were correlated in RApatients but not in healthy controls.
Authors: J A Gracie; R J Forsey; W L Chan; A Gilmour; B P Leung; M R Greer; K Kennedy; R Carter; X Q Wei; D Xu; M Field; A Foulis; F Y Liew; I B McInnes Journal: J Clin Invest Date: 1999-11 Impact factor: 14.808
Authors: M Ziolkowska; A Koc; G Luszczykiewicz; K Ksiezopolska-Pietrzak; E Klimczak; H Chwalinska-Sadowska; W Maslinski Journal: J Immunol Date: 2000-03-01 Impact factor: 5.422
Authors: David N O'Dwyer; Michelle E Armstrong; Gordon Cooke; Jonathan D Dodd; Douglas J Veale; Seamas C Donnelly Journal: Eur J Intern Med Date: 2013-08-01 Impact factor: 4.487
Authors: P Emery; E Keystone; H P Tony; A Cantagrel; R van Vollenhoven; A Sanchez; E Alecock; J Lee; J Kremer Journal: Ann Rheum Dis Date: 2008-07-14 Impact factor: 19.103